US$ 21.45
glp-1 agonist indications GLP1 medicines now address weight loss and other health conditions through innovative formulations and expanded indications, highlighting key questions about their efficacy and safety. https://ja.ma/3JZg8l3 The Role of Glucagon-Like Peptide-1
Description
Zhou, J

Documented Outcomes Prescription semaglutide and tirzepatide have undergone Phase 3 randomized controlled trials demonstrating average weight loss of 10-22 percent over 68 weeks

doi: 10.3390/biomedicines9121853

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis

Bhardwaj, P., Iyengar, N

Logistic regression was performed to obtain the propensity scores, and a greedy nearest-neighbour matching algorithm was used to perform the matching with a calliper of 0.1 pooled SD
